Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P C Waller

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Human Hypertension|October 1, 1990
Policies for managing hypertensive patients: a survey of the opinions of British specialistsP C Waller, G T McInnes, J L Reid
Postgraduate Medical Journal|November 4, 1998
Tiaprofenic acid and severe cystitisE G Brown, P C Waller, B A Sallie
British Journal of Urology|April 1, 1997
Severe cystitis associated with tiaprofenic acidM L Crawford, P C Waller, S M Wood
British Journal of Clinical Pharmacology|July 1, 1987
Lack of effect of ketanserin on indices of hepatic enzyme inductionP C Waller, G T Tucker, L E Ramsay
European Journal of Clinical Pharmacology|January 1, 1987
The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjectsP C Waller, G T Tucker, L E Ramsay
British Journal of Clinical Pharmacology|August 1, 1994
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are neededP C Waller, S M Wood, A M Breckenridge, et al.
British Journal of Clinical Pharmacology|April 1, 1994
Clinical pharmacology with confidenceP C Waller, P R Jackson, G T Tucker, et al.
Lancet (London, England)|October 24, 1987
How far to lower blood pressure?P C Waller, C G Isles, A F Lever, et al.
The British Journal of Dermatology|June 1, 1993
Dapsone-induced agranulocytosis: spontaneous reporting dataE M Cockburn, S M Wood, P C Waller, et al.
British Journal of Clinical Pharmacology|December 1, 1996
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawalJ S Price, P C Waller, S M Wood, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Human Hypertension|October 1, 1990
Policies for managing hypertensive patients: a survey of the opinions of British specialistsP C Waller, G T McInnes, J L Reid
Postgraduate Medical Journal|November 4, 1998
Tiaprofenic acid and severe cystitisE G Brown, P C Waller, B A Sallie
British Journal of Urology|April 1, 1997
Severe cystitis associated with tiaprofenic acidM L Crawford, P C Waller, S M Wood
British Journal of Clinical Pharmacology|July 1, 1987
Lack of effect of ketanserin on indices of hepatic enzyme inductionP C Waller, G T Tucker, L E Ramsay
European Journal of Clinical Pharmacology|January 1, 1987
The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjectsP C Waller, G T Tucker, L E Ramsay
British Journal of Clinical Pharmacology|August 1, 1994
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are neededP C Waller, S M Wood, A M Breckenridge, et al.
British Journal of Clinical Pharmacology|April 1, 1994
Clinical pharmacology with confidenceP C Waller, P R Jackson, G T Tucker, et al.
Lancet (London, England)|October 24, 1987
How far to lower blood pressure?P C Waller, C G Isles, A F Lever, et al.
The British Journal of Dermatology|June 1, 1993
Dapsone-induced agranulocytosis: spontaneous reporting dataE M Cockburn, S M Wood, P C Waller, et al.
British Journal of Clinical Pharmacology|December 1, 1996
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawalJ S Price, P C Waller, S M Wood, et al.
Pageof 5